| Date Filed | Type | Description |
| 10/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,154 shares
@ $3.83, valued at
$4.4k
|
|
| 07/05/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 157 shares
@ $4.1, valued at
$643.7 |
|
| 06/08/2023 |
4
| Harsch Mutya (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 40,000 options to buy
@ $4.48, valued at
$179.2k
Disposed/sold 30,000 options to buy
@ $3.46, valued at
$103.8k
|
|
| 06/02/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 3,664 shares
@ $3.4563, valued at
$12.7k
|
|
| 04/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 478 shares
@ $3.08, valued at
$1.5k
|
|
| 03/22/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Bought 10,000 shares
@ $2.5, valued at
$25k
|
|
| 01/04/2023 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,813 shares
@ $0.15, valued at
$272 |
|
| 10/04/2022 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,813 shares
@ $0.223, valued at
$404.3 |
|
| 07/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2022 |
4
| Harsch Mutya (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Granted 30,000 options to buy
@ $3.46, valued at
$103.8k
|
|
| 04/04/2022 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 3,630 shares
@ $0.65, valued at
$2.4k
|
|
| 03/18/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/12/2021 |
4
| Harsch Mutya (Director) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Granted 40,000 options to buy
@ $4.41, valued at
$176.4k
|
|
| 10/12/2021 |
3
| Harsch Mutya (Director) has filed a Form 3 on Satsuma Pharmaceuticals, Inc. |
| 10/01/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2020 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on VYNE Therapeutics Inc.|
Txns:
| Granted 10,460 shares
@ $1.445, valued at
$15.1k
|
|
| 10/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/08/2020 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 150,000 shares
@ $0
Granted 150,000 options
@ $1.95, valued at
$292.5k
|
|
| 04/07/2020 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Granted 26,381 shares
@ $0
Granted 92,302 shares
@ $0
Paid exercise price by delivering 4,474 shares
@ $1.4, valued at
$6.3k
|
|
| 04/02/2020 |
4
| Harsch Mutya (Chief Legal Officer and GC) has filed a Form 4 on Menlo Therapeutics Inc.|
Txns:
| Paid exercise price by delivering 1,688 shares
@ $2.68, valued at
$4.5k
|
|
| 03/11/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/11/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/11/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/24/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/03/2019 |
4
| Harsch Mutya (CLO and General Counsel) has filed a Form 4 on Foamix Pharmaceuticals Ltd.|
Txns:
| Granted 4,284 shares
@ $2.159, valued at
$9.2k
|
|
| 10/02/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|